Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Micha Levi

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|March 19, 2013
Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid ArthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Clinical Pharmacology|February 26, 2013
Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2007
Population pharmacokinetics of nicotine and its metabolites I. Model developmentMicha Levi, Delia A Dempsey, Neal L Benowitz, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2007
Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model applicationMicha Levi, Delia A Dempsey, Neal L Benowitz, et al.
European Journal of Internal Medicine|December 3, 2014
Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: A historical prospective studyAmos Levi, Eytan Cohen, Micha Levi, et al.
Headache|May 24, 2020
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy ResponsesJill Fiedler-Kelly, Julie Passarell, Elizabeth Ludwig, et al.
Biopharmaceutics & Drug Disposition|January 13, 2004
Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostineMicha Levi, Susan J DeRemer, Chunzhi Dou, et al.
British Journal of Clinical Pharmacology|September 16, 2016
Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapyXiaoying Xu, Dmytro Khadzhynov, Harm Peters, et al.
Frontiers in Pharmacology|January 23, 2025
stormTB: a web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatmentsRoberto Visintainer, Anna Fochesato, Daniele Boaretti, et al.
Hepatology (Baltimore, Md.)|December 31, 2013
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patientsJeremie Guedj, Jing Yu, Micha Levi, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|March 19, 2013
Exposure-Exposure Relationship of Tocilizumab, an Anti-IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid ArthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Clinical Pharmacology|February 26, 2013
Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritisMicha Levi, Susan Grange, Nicolas Frey
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2007
Population pharmacokinetics of nicotine and its metabolites I. Model developmentMicha Levi, Delia A Dempsey, Neal L Benowitz, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 9, 2007
Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model applicationMicha Levi, Delia A Dempsey, Neal L Benowitz, et al.
European Journal of Internal Medicine|December 3, 2014
Elevated serum homocysteine is a predictor of accelerated decline in renal function and chronic kidney disease: A historical prospective studyAmos Levi, Eytan Cohen, Micha Levi, et al.
Headache|May 24, 2020
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy ResponsesJill Fiedler-Kelly, Julie Passarell, Elizabeth Ludwig, et al.
Biopharmaceutics & Drug Disposition|January 13, 2004
Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostineMicha Levi, Susan J DeRemer, Chunzhi Dou, et al.
British Journal of Clinical Pharmacology|September 16, 2016
Population pharmacokinetics of daptomycin in adult patients undergoing continuous renal replacement therapyXiaoying Xu, Dmytro Khadzhynov, Harm Peters, et al.
Frontiers in Pharmacology|January 23, 2025
stormTB: a web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatmentsRoberto Visintainer, Anna Fochesato, Daniele Boaretti, et al.
Hepatology (Baltimore, Md.)|December 31, 2013
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patientsJeremie Guedj, Jing Yu, Micha Levi, et al.
Pageof 3